US · ABVC
ABVC BioPharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Fremont, CA 94538
- Website
- abvcpharma.com
Price · as of 2024-12-31
$1.03
Market cap 18.98M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $89.16 | +8,556.31% |
| Intrinsic Value(DCF) | $9,273.20 | +900,210.68% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $21,496.81 | $0.00 | $0.00 | ||
| 2011 | $20,636.94 | $572,963.68 | $0.00 | $0.00 | $1,667,616.30 |
| 2012 | $2,292.99 | $2,779,300.90 | $0.00 | $0.00 | $0.00 |
| 2013 | $286.62 | $6,353,295.05 | $85,048.98 | $0.00 | $0.00 |
| 2014 | $2,292.99 | $6,885,799.00 | |||
| 2015 | $1,433.12 | ||||
| 2016 | $360.00 | ||||
| 2017 | $360.00 | ||||
| 2018 | $270.00 | $0.00 | $0.00 | ||
| 2019 | $29.00 | $1,524.67 | $37,412.30 | $0.00 | $0.00 |
| 2020 | $45.00 | $46.29 | $527.12 | $0.00 | $107.83 |
| 2021 | $22.80 | $59.19 | $25.49 | $0.00 | $87.74 |
| 2022 | $5.91 | $28.64 | $5,301.37 | $0.00 | $0.00 |
| 2023 | $1.25 | $162.47 | $1.25 | $0.00 | $130.07 |
| 2024 | $0.64 | $89.16 | $6,324.69 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates ABVC BioPharma, Inc.'s (ABVC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $89.16
- Current price
- $1.03
- AI upside
- +8,556.31%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9,273.20
+900,210.68% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ABVC | ABVC BioPharma, Inc. | $1.03 | 18.98M | +8,556% | +900,211% | — | — | -1.42 | 6.08 | 14.64 | -2.24 | — | 6.08 | 99.85% | -923.34% | -962.12% | -378.31% | -131.15% | -68.64% | 2.61 | -5.70 | 0.33 | 0.32 | -0.54 | -7667.00% | 23431.00% | -5701.00% | -24.25% | -0.28 | -51.48% | 0.00% | 0.00% | 0.10% | -2.07 | -5.38 | 19.10 | -14.83 |
| FGEN | FibroGen, Inc. | $9.07 | 36.69M | +230% | -59% | — | +42% | -19.49 | -4.11 | 31.31 | -6.67 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 63.58% | -14.91% | -0.32 | -18.24 | 1.47 | 0.60 | -0.16 | -8356.00% | -3671.00% | -5646.00% | -14.91% | -1.04 | 58.55% | 0.24% | -4.70% | 3.92% | -6.32 | -6.87 | 32.07 | -12.76 |
| GRCE | Grace Therapeutics, Inc. | $4.29 | 60.61M | — | — | — | — | -3.75 | 0.54 | — | -0.83 | — | 2.07 | 0.00% | — | — | -14.91% | -30.04% | -13.17% | 0.00 | — | 11.77 | 11.53 | 1.33 | -5434.00% | — | 2063.00% | -41.52% | -7.72 | -35.82% | 0.00% | 0.00% | 0.00% | -0.83 | -0.92 | — | -0.71 |
| JUNS | Jupiter Neurosciences, In… | $0.53 | 18.25M | — | — | — | — | -7.90 | 4.62 | — | -7.18 | — | 4.62 | 0.00% | — | — | 299.46% | 208.79% | -76.83% | 0.05 | -12.45 | 2.31 | 1.88 | 1.62 | -3943.00% | — | 71318.00% | -20.28% | -1.95 | 264.16% | 0.00% | 0.00% | 29.93% | -5.09 | -4.02 | — | -1.31 |
| LTRN | Lantern Pharma Inc. | $2.82 | 31.54M | — | — | — | — | -1.90 | 1.86 | — | -0.70 | 0.00 | 1.86 | 0.00% | — | — | -66.93% | 1620.51% | -60.04% | 0.01 | — | 5.83 | 5.54 | 0.33 | 13125510.00% | — | 2409.00% | -45.25% | -4.11 | 1300.25% | 0.00% | 0.00% | 0.00% | -0.70 | -0.88 | — | -0.66 |
| LVTX | LAVA Therapeutics N.V. | $1.74 | 45.77M | +2,166% | +1,689% | — | — | -1.54 | 1.39 | 3.22 | 1.39 | — | 1.39 | 100.00% | -247.81% | -209.60% | -63.64% | 72.75% | -27.52% | 0.19 | -57.66 | 4.40 | 4.25 | 1.27 | -4013.00% | 7701.00% | -5229.00% | -50.64% | -1.09 | 47.94% | 0.00% | 0.00% | 0.00% | 1.10 | 1.67 | -2.73 | -2.75 |
| PDSB | PDS Biotechnology Corpora… | $0.68 | 36.94M | — | — | — | — | -1.19 | 2.36 | — | -0.74 | — | 2.36 | 0.00% | — | — | -166.65% | 954.97% | -71.81% | 1.15 | -7.77 | 2.64 | 2.44 | 0.59 | -2590.00% | — | 423.00% | -78.19% | -2.05 | 943.09% | 0.00% | 0.00% | 0.00% | -0.69 | -0.71 | — | -6.50 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| TVRD | Tvardi Therapeutics, Inc. | $3.99 | 37.43M | +2,851% | +48% | — | +64,129% | -0.32 | -4.89 | 3.15 | -0.46 | -0.01 | -4.89 | 88.62% | -781.57% | -992.95% | 212.65% | 134.22% | -200.11% | -9.68 | -6.58 | 11.03 | 10.67 | -0.10 | 241838.00% | -6596.00% | 19450.00% | -276.02% | -15.34 | 149.93% | 0.00% | 0.00% | 0.00% | -0.52 | -0.47 | 4.06 | -26.80 |
| XLO | Xilio Therapeutics, Inc. | $0.53 | 27.74M | — | — | — | — | -0.84 | 2.76 | 7.67 | -0.03 | — | 2.76 | 100.00% | -954.95% | -918.05% | -214.02% | 466.54% | -88.24% | 0.46 | -605.82 | 2.21 | 2.03 | 0.81 | -6079.00% | — | -7335.00% | -37.86% | -0.67 | 141.80% | 0.00% | 0.00% | 28.58% | -0.02 | -0.08 | 0.24 | -9.18 |
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
- CEO
- Uttam Yashwant Patil
- Employees
- 16
- Beta
- 0.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9,273.20 ÷ $1.03) − 1 = +900,210.68% (DCF, example).